[Asia Economy Reporter Jang Hyowon] Vibozone Pharmaceutical has been on a six-day winning streak. This is attributed to the news that the Phase 3 clinical trial of a non-opioid analgesic was successful in South Korea.
As of 9:43 AM on the 9th, Vibozone Pharmaceutical is trading at 1,650 KRW, up 11.9% from the previous day.
According to industry sources, Vibozone Pharmaceutical announced that the Phase 3 clinical trial results of Opiranjerin Injection confirmed its analgesic efficacy and safety. Opiranjerin is a non-opioid analgesic with strong pain-relieving effects for moderate to severe pain, including postoperative pain. It works by inhibiting substances that transmit pain signals, exerting its effects on both the central and peripheral nervous systems.
The Phase 3 clinical trial of Opiranjerin Injection was conducted on 285 patients experiencing pain after laparoscopic colorectal surgery in South Korea. The clinical trial was carried out at five institutions: Seoul National University Hospital, Asan Medical Center, Bundang Seoul National University Hospital, Korea University Anam Hospital, and Samsung Medical Center.
Vibozone Pharmaceutical expects the global non-opioid analgesic market to grow to 100 trillion KRW by 2030. Although opioid analgesics, which are administered to patients with severe pain such as postoperative pain and neuropathic pain, have a high risk of addiction and a sharp increase in deaths due to misuse, there are no alternatives, resulting in significant unmet medical needs.
Vibozone Pharmaceutical plans to proceed with the domestic approval process for Opiranjerin Injection with the Ministry of Food and Drug Safety within the first half of this year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
